At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
JUNS Jupiter Neurosciences
Closed Good Friday 04-17 16:00:00 EDT
0.6200
-0.0867
-12.27%
盘后0.6138
-0.0062-1.00%
19:48 EDT
| High0.6690 | Low0.6006 | Vol100.00K |
| Open0.6502 | D1 Closing0.7067 | Amplitude9.68% |
| Mkt Cap20.52M | Tradable Cap9.40M | Total Shares33.10M |
| T/O63.30K | T/O Rate0.66% | Tradable Shares15.17M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
BRIEF-Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development
Reuters · 04-08
Jupiter Neurosciences: to Initiate Jns115 Parkinson’s Phase 2a Trial in Q3 2025
THOMSON REUTERS · 04-08
Jupiter Neurosciences Inc - Does Not Anticipate Impact From U.S. Tariffs on Clinical-Stage Prescription Product Development
THOMSON REUTERS · 04-08
Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
GlobeNewswire · 04-08
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ACCESS Newswire · 03-07
BRIEF-Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products
Reuters · 03-04
Jupiter Neurosciences Inc - First Three Products Expected to Launch in Q3 2025
THOMSON REUTERS · 03-04
Jupiter Neurosciences and Aquanova Ag Announce Strategic Collaboration to Develop Longevity and Healthspan Products
THOMSON REUTERS · 03-04
Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
GlobeNewswire · 03-04
Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’
TIPRANKS · 02-04
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
GlobeNewswire · 02-04
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules
MT Newswires Live · 02-03
Jupiter Neurosciences Announces Jotrol Manufacturing Agreement With Catalent to Support Phase 2a Parkinson’s Trial
THOMSON REUTERS · 02-03
Jupiter Neurosciences- Under Terms, Catalent to Manufacture Clinical Batches of Jotrol for Parkinson's Study
THOMSON REUTERS · 02-03
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
GlobeNewswire · 02-03
Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study
MT Newswires Live · 01-30
Jupiter Neurosciences Partners With Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
THOMSON REUTERS · 01-30
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
GlobeNewswire · 01-30
Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures
MT Newswires Live · 01-24
Investors Look Ahead to PMI, Home Price Data as US Futures Tread Water in Friday's Premarket
MT Newswires Live · 01-24
Introduction
Company Name.
Jupiter Neurosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App